Q-omics provides the consensus-scored YBX1 profile across patient tissues and cancer cell-line models. YBX1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, YBX1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, YBX1 protein abundance shows 30,362 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where YBX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YBX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YBX1 survival associations across molecular data types. YBX1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YBX1 RNA expression–survival associations across cancer types. High YBX1 expression shows unfavorable associations in ACC, KIRP, LIHC, MESO, SARC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for YBX1 RNA expression.
This table summarizes YBX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for YBX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YBX1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, KIRC, LUSC and COAD. The HNSC box plot shows higher YBX1 RNA expression in tumor versus normal tissue (log2 FC = +0.948, t-test p < 0.001).
This table shows molecular features associated with YBX1 in patient tissues and cancer cell lines. In patient samples, YBX1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, YBX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
